Cetuximab-Conjugates Nanoparticles for the Treatment of Triple Negative Breast Cancer

doi 10.11159/nddte19.104
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Avestia Publishing

Related search

Targeting MYC for Triple-Negative Breast Cancer Treatment

Oncoscience
Cancer ResearchOncology
2018English

Cetuximab PET Delineated Changes in Cellular Distribution of EGFR Upon Dasatinib Treatment in Triple Negative Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2020English

Targeted Nanoparticles for Image-Guided Treatment of Triple-Negative Breast Cancer: Clinical Significance and Technological Advances

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
MedicineBioengineeringNanotechnologyBiomedical EngineeringNanoscience
2015English

Triple-Negative Breast Cancer

2018English

Silencing the Roadblocks to Effective Triple-Negative Breast Cancer Treatments by siRNA Nanoparticles

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2017English

Systemic Administration of siRNA With Anti-Hb-Egf Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer

English

Layer-By-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment

ACS Nano
Materials ScienceNanoscienceEngineeringNanotechnologyAstronomyPhysics
2013English

Platinum-Based Therapy for Triple-Negative Breast Cancer Treatment: A Meta-Analysis

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy